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In this issue, Qiu and colleagues [1] demonstrate in vitro and in vivo activity of a triterpene glycoside
from black cohosh. The isolated compound acts as a suppressor of osteoclastogenesis, targeting
specifically RANKL, a member of the TNF superfamily.Bone-related diseases, such as Pa-
get’s disease, osteoporosis, arthritis,
or cancer metastases, affect millions
of people worldwide. Bones are con-
stantly remodeled through the synthe-
sis of bone matrix by osteoblasts and
the resorption of bone by osteoclasts.
Osteoblasts and osteoclasts arise
from distinct cell lineages and matu-
ration processes—osteoclasts arise
from mesenchymal stem cells while
osteoclasts differentiate from hemato-
poietic monocyte/macrophage pre-
cursors [2]. One of the key factors738 Chemistry & Biology 14, July 2007 ªmediating the process of osteoclast
formation known as osteoclastogene-
sis is receptor activator of nuclear
factor-kappaB (NF-kB) ligand (RANKL),
a member of the tumor necrosis factor
(TNF) family that has also been called
osteoclast differentiation factor, TNF-
related activation-induced cytokine,
and osteoprotegerin (OPG) ligand [3].
RANKL, protein expressed on the
surface of osteoblastic/stromal cells,
is directly involved in the differentiation
of monocyte macrophages into osteo-
clasts [4]. Mice with disruptions in the2007 Elsevier Ltd All rights reservedRANKL gene show a lack of osteo-
clasts, severe osteopetrosis, and de-
fective tooth eruption, indicating that
RANKL-induced osteoclastogenesis
is mediated through the cell surface
receptor RANK [5]. That RANK can
mediate osteoclastogenesis was first
demonstrated by Hsu and coworkers
in 1999 [6]. Further gene-deletion
analysis of RANK, RANKL, and TNF
receptor-associated factor 6 (TRAF6)
showed that these genes are positive
regulators of osteoclastogenesis [7],
whereas OPG, a decoy receptor forTable 1. Current Drugs Used for Bone Loss Related Disorders
Drug Chemical Class Mechanism of Action Side Effects
Alendronate/Risedronate/
Ibandronate/Zoledronic Acid
Bisphosphonates Inhibits osteoclast GI toxicity, weight loss,
bone pain, low calcium levels
Estrogen Sex steroid Inhibits osteoclast development Endometrial cancer, stroke
Raloxifene Estrogen mimic Inhibits osteoclast development Leg cramps, hot flashes
Estren Estrogen derivative Inhibits osteoblast apoptosis Breast cancer
Denosumab RANKL antibody Inhibits osteoclast development Nausea, diarrhea, cramps
Calcitonin Peptide hormone Inhibits osteoclasts Nausea, skin redness, diarrhea
Teriparatide Peptide Induces bone formation Pain, headache, diarrhea
PTHrP Osteotrophin Induces bone formation Nausea, weakness
GI, gastrointestinal; RANKL, receptor activator of NF-kB ligand; PTHrP, parathyroid hormone-related peptide.
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(A) Black cohosh, its uses, and chemical structure of its active constituent ACCX.
(B) Suppression of osteoclastogenesis by natural agents.RANKL, was found to be a negative
regulator of this process [8]. RANKL-
induced osteoclastogenesis is medi-
ated through the cell surface receptor
RANK. Through the recruitment of the
adaptor proteins TRAF6 and NF-
kB-inducing kinase (NIK), RANK acti-
vates transcription factor NF-kB and
mitogen activated protein kinases
(MAPK), such as c-Jun NH2-terminal
kinase (JNK), p38, and extracellular
signal-regulated kinases (ERK1/2)
signaling pathways [9]. Chronic inflam-
mation is also an important mediator
of osteoclastogenesis and a recent
report indicates that people with the
greatest number of inflammatory
markers have the highest risk of osteo-
porotic fractures [10]. Current treat-ments for osteoporosis include estro-
gens and selective estrogen receptor
modulators for suppressing osteoclast
formation; and bis-phosphonates and
calcitonin for suppressing osteoclast
activity. However, most of these thera-
pies have severe side effects, such as
gastrointestinal toxicity and nausea
(Table 1). Some new drug therapies
for osteoporosis are on the horizon,
such as an antibody against RANKL
(Denosumab) that has been shown to
increase bone mineral density and
decrease bone resorption in post-
menopausal women with low bone
mass [11].
Because products from natural
sources are safe and inexpensive,
demonstration that they are also effi-Chemistry & Biology 14, July 2007 ª2cacious has a tremendous potential
for the treatment of bone-related dis-
orders. Several agents from natural
sources such as curcumin (from tur-
meric), guggulsterone (from the gug-
gul), and 10-acetoxychavicol acetate
(ACA; from Asian ginger) have been re-
ported to suppress RANKL signaling
and consequent osteoclastogenesis
[12–14]. Most of these studies were
done in cell cultures. Qiu and col-
leagues describe a compound from
black cohosh thatmay have a potential
against osteoporosis, based on their
in vitro and in vivo studies [1]. Black
cohosh, or Actaea racemosa, is a plant
native to North America whose roots
and rhizomes are widely used in the
treatment of menopausal symptoms,007 Elsevier Ltd All rights reserved 739
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insomnia, and anxiety (Figure 1A). This
plant has also been shown to pos-
sess diuretic, antidiarrheal, and anti-
inflammatory activity [15]. Qiu and
colleagues showed that 25-acetylci-
migenol xylopyranoside (ACCX), a cy-
cloartane triterpenoid glycoside
isolated from black cohosh, blocks
osteoclastogenesis induced by either
RANKL or TNF-a, with inhibition of
the NF-kB and ERK signaling path-
ways [1]. Interestingly, they also
demonstrated the efficacy of this
compound on suppression of TNF-a-
induced bone loss in vivo. They found
that ACCX suppresses RANKL-
induced activation of the NF-kB path-
way as indicated by lack of phos-
phorylation and degradation of IkBa
and inhibition of NF-kB DNA binding
activity. They also observed that
this triterpene downregulated RANKL-
induced expression of NF-kB regu-
lated genes, such as TNF-a- and
toll-like receptor-2 (TLR2). RANKL-
induced activation of MAPKs was
also modulated by ACCX. They found
that this compound induced inhibition
of ERK activation whereas it activated
p38 and JNK MAPKs.
This novel glycoside also inhibited
TNF-a-induced osteoclastogenesis in
vitro. This effect of ACCX was medi-
ated through suppression of TNF-a-
induced activation of NF-kB and ERK
pathways. Most importantly, it was
found that ACCX inhibited TNF-a-
induced bone loss in vivo. These
findings clearly establish that ACCX740 Chemistry & Biology 14, July 2007 ªdirectly suppresses osteoporosis (Fig-
ure 1B), but it is not clear whether other
components of black cohosh may also
have a role in suppression of osteo-
clastogenesis. It is also not known
whether ACCX can induce production
of OPG in osteoblasts and therefore in-
directly inhibit osteoclastogenesis.
The identification of RANKL, RANK,
andOPGaskeyplayers in osteoclasto-
genesis has created new possibilities
for designing highly effective and ratio-
nal drugs to treat bone loss in millions
of patients. Although targeting RANKL
appears to be the most efficient and
relevant approach for the treatment of
bone loss, other strategiesmight be re-
quired to minimize potential side ef-
fects on other organs such as the in-
nate and adaptive immune systems.
Although numerous treatments for var-
ious bone-related disorders have been
identified, they suffer from various
drawbacks, such as lack of efficacy,
excessive side effects, and high
cost. Plant-derived products such as
ACCX, curcumin, guggulsterone,
ACA, and several others offer much
promise for the treatment of diseases
associated with bone loss but they re-
quire extensive investigation in various
preclinical and clinical settings to
prove their usefulness.
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